Modality
Degrader
MOA
AuroraAi
Target
SMN2
Pathway
Incretin
Endometrial CaCMLWet AMD
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
Sep 2020
→ Aug 2028
Phase 1Current
NCT05964318
1,771 pts·CML
2020-09→2028-08·Recruiting
1,771 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-062.4y awayInterim· CML
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2028-08-06 · 2.4y away
CML
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05964318 | Phase 1 | CML | Recruiting | 1771 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |